1/64
Looks like no tags are added yet.
Pharmaceutical Development
transforming an Active Pharmaceutical Ingredient into a finished medicinal product suitable for handling, distribution and patient administration
Quality Target Product Profile
establishes the ideal dosage form, strength, release profile, shelf-life, and route of administration based on patient needs and biopharmaceutical requirements
Aqueous Solubility
key determinant of drug absorption and BA
a drug must be in solution to be absorbed
Surface reaction
drug molecules detach from the solid into stagnant boundary layer next to it
Mass Transfer
molecules diffuse from the boundary layer into the bulk solution
Stability
a drug product for routine use is expected to have a shelf-life of at least 3 years presenting less than 5% decomposition and no significant physical change under normal storage conditions
Accelerated Stability Testing
Typically exposing formulations to elevated temperatures and relative humidities (such as 40 C/75% RH) for 1 to 4 weeks
Quality by Design
Formulation of an active substance into a dosage form involves
careful designing, using good science and common sense. This
systematic approach is usually referred
Micelles
Lipophilic drugs dissolve in the core, reaching concentrations far above their aqueous solubility
Liposomes
Can carry a PEG polymer coat and antibody targeting
molecules
Nanotechnology
Great potential for targeted delivery in cancer and organ-
specific delivery (e.g.,CNS)
Modified release formulations
shorten onset or prolong duration of action
➔ Absorption rate is then set by the release rate from the dosage
form
Sustained Release
gradual absorption to reach a steady level for hours or days
Delayed release
for oral drugs unstable at the low pH of the stomach
Controlled release
specialized devices allow the release rate to be adjusted as needed
Clinical development
generate sufficient understanding of safety and efficacy to support marketing authorization
Phase I
preliminary understanding of a new medicine’s clinical pharmacology
First-in-Human Studies
conducted in healthy volunteers, focused mainly on PK and safety
Single ascending dose
6-10 dose levels, 2+ cohorts; typically 4 active + placebo per cohort
Sentinel dosing
one active + one placebo subject dose first and observed before the rest of the cohort
Multiple Ascending dose
follows duration informed by half-life, aims to characterize steady-state PK
Linear Kinetics
proportional increase in Cmax/AUC with dose
Nonlinear Kinetics
disproportionate increase
may indicate absorption saturation or reduced clearance
Phase II POC
the make or break study for most drugs in development
Phase III
principally supports registration; must provide substantial evidence for risk/benefit assessment to support marketing authorization
Thorough OT
assesses risk of drug-induced QT prolongation
(torsades de pointes risk) via regular ECGs at therapeutic/
supratherapeutic doses
Bioequivalence
required if formulation changes – new
formulation’s exposure must fall within 80-125% of key PK
parameters vs. origina
Drug Interactions
PK or PD mechanisms; drugs as
“perpetrators” or “victims”; modelling/ simulation increasingly
predicts which interactions are clinically significant
Phase IV
Safety database at registration is typically limited; regulators
may require post-marketing safety information
conducted after authorization– two
categories: regulator required safety studies, and sponsor-
initiated studies extending indications
Phase 0 (microdose)
shorter toxicology package (<14
days); pharmacologically inactive microdose used to establish PK
properties before committing to full development
Clinical Imaging in Drug Development
To provide tools for more direct translation of biological
understanding from animals to humans
Positron Emission Tomography
Uses radiolabeled ligands that bind selectively to a
biological target
Magnetic Resonance Imaging
Relies on the magnetic properties of hydrogen nuclei in the
body
Structural MRI
provides 3D anatomical images of organs
and tumors
Contrast-enhanced MRI
uses agents like Gadolinium to
highlight blood flow or a disrupted BBB
Functional MRI
measures blood oxygenation changes to
map neuronal activity
Computed Tomography
X-ray based method primarily for anatomical screening and
tumor size monitoring in oncology
PET-CT
combining molecular and structural data to reduce
artifacts and provide better localization
Intellectual Property
refers to creations of the mind
it can be an invention (patent/utility model), a design (industrial design), a brand name (trademark, or a literary and artistic work)
Patent
A grant by a nation state or supranational body of the exclusive right to commercialize an invention in that state for a limited time
Novelty
The invention must not have been known to the public anywhere in the world before the filing date (no prior art)
Inventive step
the invention must not be obvious to a person skilled in the art (e.g., standard medicinal chemist)
Industrial Applicability
The invention must be capable of being made or used in an
industry
The State of the Art
All published material in the technical field up to the relevant
date
Regulatory Affairs
ensures that a pharmaceutical company complies with all regulations governing the development, manufacturing, and marketing of medicinal products
1937 Elixir Sulfanilamide
Led to the 1938 US Food, Drug and Cosmetics Act after 107
people died from toxic solvent ingestion
1961 Thalidomide Disaster
Phocomelia
● Note: that these tragedies drugs be proven forced both safe government to mandate and effective before they are sold
Development Phase
➔ Pricing strategy and marketing plans are prepared before
launch.
Introduction
This is must where marketing spend is highest and the product must be available in all outlets, such as pharmacies
Direcgt to consumer advertising
Direct marketing to patients in print, television and radio, legally
permitted in only a few countries, such as the US and New
Zealand
Blockbuster
is a drug that generates over 1 billion in anual sales
Target Validation
Uses “chemical probes” (imaging ligands) to prove a target’s
role in a tissue before full drug development.
Biodistribution
Confirms the drug reaches the tissue
Warning: species differences are common; a drug might penetrate the BBB in rats but not in humans
Target Interaction
Measuring receptor occupancy – how much of the target
is “occupied” by drug at different doses.
Pharmacodynamics
Measuring the biological response (e.g., FDG-PET to
measure glucose metabolism in tumors or the brain)
Growth
The market accepts the product and market share grows;
marketing becomes more targete
Maturity
The market no longer grows, and this is the most profitable stage
Decline
Increased competition and loss of sales and profits,
generally at the end of patent life
Market dynamics
Marketing teams data from standard must assess sources (e.g., the therapeutic IQVIA) to area using identify target
physician segments
Competitor Assessment
analyze competitor’s sales volumes, investment levels and promotional messages
Key opinion leaders
“Thought leaders” are respected individuals in a therapeutic area,
such as prominent medical school faculty, who influences physicians through their personal status
Market Access
defined as the process of ensuring a medicine is available to patients and funded by health system
Value based pricing
Setting a price based on the perceived value of the health
benefit provided, rather than just the cost of production
International reference pricing
governments setting prices by comparing what other countries pay for the same drug
Tendering
a competitive process where companies bid to supply a drug to a hospital or health system